Tebentafusp for untreated metastatic uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision clinical trials.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific genetic marker called HLA-A*0201, confirmed by a blood test.
- You cannot have received any prior treatments for uveal melanoma that has spread, including chemotherapy or targeted therapy.
- You cannot have had any treatments directed to the liver (like chemo or radiation) for your cancer.
- Your overall health must be good enough that you can perform daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans, and you must be willing to have a new biopsy of a tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests a combination of two drugs (tebentafusp and a liver-directed treatment called LDT) for people with uveal melanoma that has spread to the liver. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.